References
- Singh G, Singh BR. Is fosfomycin as effective as claimed on MDR gram-negative bacteria causing UTI? Infect Drug Resist. 2019;12:2711–2712. doi:10.2147/IDR.S22476931564920
- Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. Indian J Urol. 2017;33:149–154. doi:10.4103/iju.IJU_285_1628469304
- Tulara NK. Nitrofurantoin and fosfomycin for extended spectrum beta-lactamases producing escherichia coli and klebsiella pneumoniae. J Global Infect Dis. 2018;10:19–21. doi:10.4103/jgid.jgid_72_17
- Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100 Twenty-Ninth Edition. Wayne, USA: CLSI; 2019.
- European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameter, version9.0, valid from 2019-01-01; 2019 Available from: http://www.eucast.org/. Accessed 821, 2019.